Skip to Main content Skip to Navigation
Journal articles

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

Abstract : Although the development of mitogen-activated protein kinase (MAPK) inhibitors has greatly improved the prognosis of BRAF V600 cutaneous melanomas, the identification of molecular indicators for mutated patients at risk of early progression remains a major issue. Using an amplicon-based next-generation-sequencing (NGS) assay that targets cancer-related genes, we investigated co-occurring alterations in 89 melanoma samples. We analyzed both their association with clinicopathological variables and clinical significance in terms of progression-free survival (PFS) and overall survival (OS) according to BRAF genotyping. Among co-occurring mutations, TERT promoter was the most frequently mutated gene. Although no significant difference in PFS was observed in the presence or absence of co-occurring alterations to BRAF V600 , there was a trend of longer PFS for patients harboring TERT c.-124C>T mutation. Of most interest, this mutation is an independent marker of good prognosis in subgroups of patients with poor prognosis (presence of brain metastasis and elevated level of lactate dehydrogenase, LDH). Moreover, combination of elevated LDH level, presence of brain metastasis, and TERT c.-124C>T mutation was identified as the best fit model for predicting clinical outcome. Our work revealed the potential interest of c.-124C>T status determination in order to refine the prognosis of BRAF V600 melanoma under mitogen-activated protein kinase (MAPK) inhibitors.
Document type :
Journal articles
Complete list of metadata

Cited literature [50 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02964369
Contributor : Michel Salzet <>
Submitted on : Monday, October 12, 2020 - 1:32:41 PM
Last modification on : Wednesday, March 17, 2021 - 2:32:03 PM
Long-term archiving on: : Wednesday, January 13, 2021 - 6:51:20 PM

File

Etienne 2.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Pauline Blateau, Etienne Coyaud, Estelle Laurent, Benoit Béganton, Vincent Ducros, et al.. TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. Cancers, MDPI, 2020, 12 (8), pp.2224. ⟨10.3390/cancers12082224⟩. ⟨inserm-02964369⟩

Share

Metrics

Record views

55

Files downloads

83